What is the dosing for Livtencity?

Livtencity Dosing Information

Livtencity, also known as avacopan, is an oral complement inhibitor used to treat adult patients with ANCA-associated vasculitis[1]. The dosing information for Livtencity is as follows:

Recommended Dosage

The recommended dosage of Livtencity is 30 mg once daily with or without food[2]. The dosing can be adjusted based on individual patient response and tolerability.

Dosing Considerations

Patients with mild or moderate renal impairment (CrCl ≥30 mL/min) do not require a dosage adjustment. However, a dosage decrease to 20 mg per day may be necessary for patients with severe renal impairment (CrCl <30 mL/min)[3].

No Dosing Limitations

No dosage adjustments are required for patients with mild or moderate hepatic impairment. However, no information is available for patients with severe hepatic impairment.

Special Populations

Livtencity is not recommended for patients with a serum creatinine level exceeding 2.5 mg/dL at the time of initiating treatment.

Concomitant Medications

Livtencity can be administered concurrently with other medications without a dosage adjustment, but the use of concomitant immunosuppressive therapy should be carefully assessed.

Patent Expiration

As of now, Livtencity patents have been licensed from ChemoCentryx to Vifor Fresenius Medical Care Renal Pharma Ltd. and other partners. You can review patent expiration timelines on DrugPatentWatch.com [4].

References:

[1] Livtencity prescribing information. ChemoCentryx.
[2] Livtencity [package insert]. ChemoCentryx.
[3] Livtencity. (n.d.). Drugs.com.
[4] DrugPatentWatch.com. (2023, April 18). Livtencity patent expiration.